×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NGNE – neurogene inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NGNE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13
08:11 am
ngne
Neurogene (NASDAQ:NGNE) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.
High
Report
Neurogene (NASDAQ:NGNE) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.
11/12
04:27 pm
ngne
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome [Yahoo! Finance]
High
Report
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome [Yahoo! Finance]
11/12
04:01 pm
ngne
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
High
Report
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
11/6
08:18 am
ngne
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
Low
Report
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
11/6
07:30 am
ngne
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Medium
Report
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
11/5
04:01 pm
ngne
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/31
07:19 am
ngne
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Date
Time
Symbol
Headline
Impact
12/15
06:00 pm
ngne
Form SCHEDULE 13G Neurogene Inc. Filed by: Trails Edge Capital Partners, LP
Medium
Report
Form SCHEDULE 13G Neurogene Inc. Filed by: Trails Edge Capital Partners, LP
11/14
03:46 pm
ngne
Form SCHEDULE 13G/A Neurogene Inc. Filed by: EcoR1 Capital, LLC
Low
Report
Form SCHEDULE 13G/A Neurogene Inc. Filed by: EcoR1 Capital, LLC
11/12
05:12 pm
ngne
Form 8-K Neurogene Inc. For: Nov 12
High
Report
Form 8-K Neurogene Inc. For: Nov 12
11/6
07:31 am
ngne
Form 8-K Neurogene Inc. For: Nov 06
Medium
Report
Form 8-K Neurogene Inc. For: Nov 06
10/9
07:01 am
ngne
Form 8-K Neurogene Inc. For: Oct 09
High
Report
Form 8-K Neurogene Inc. For: Oct 09
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: